His primary areas of study are Microbiology, Klebsiella pneumoniae, Antibiotics, Drug resistance and Antibacterial agent. His studies deal with areas such as Genetics, Gene, Enterobacteriaceae and Acinetobacter baumannii as well as Microbiology. His Acinetobacter baumannii research incorporates themes from Multiple drug resistance, Mutant, Acinetobacter, Autoinducer and Mobile genetic elements.
Robert A. Bonomo combines subjects such as Colistin, Carbapenem, Imipenem, Bacteremia and Internal medicine with his study of Klebsiella pneumoniae. His Antibiotics study integrates concerns from other disciplines, such as Biotechnology, Intensive care medicine, Combination therapy and Global health, Public health. His Antibacterial agent research is multidisciplinary, incorporating perspectives in Ceftazidime, Molecular epidemiology and Virology.
Robert A. Bonomo mainly focuses on Microbiology, Klebsiella pneumoniae, Antibiotics, Acinetobacter baumannii and Stereochemistry. The various areas that he examines in his Microbiology study include Ceftazidime and Enterobacteriaceae, Escherichia coli. His Klebsiella pneumoniae research focuses on Plasmid and how it relates to Virology.
His work deals with themes such as Antimicrobial, Intensive care medicine and Bacteria, which intersect with Antibiotics. His Acinetobacter baumannii research includes themes of Colistin, Drug resistance and Acinetobacter. His study looks at the relationship between Stereochemistry and fields such as Beta-Lactamase Inhibitors, as well as how they intersect with chemical problems.
His primary scientific interests are in Microbiology, Antibiotics, Klebsiella pneumoniae, Acinetobacter baumannii and Antibiotic resistance. His Microbiology research includes elements of Pseudomonas aeruginosa and Avibactam. His research integrates issues of Piperacillin/tazobactam and Escherichia coli in his study of Antibiotics.
He has researched Klebsiella pneumoniae in several fields, including Plasmid, Internal medicine, Aztreonam and Meropenem. His Acinetobacter baumannii study incorporates themes from Efflux, Transcriptome and Gene, Virulence. Robert A. Bonomo interconnects Antimicrobial, Enterobacteriaceae and Drug resistance in the investigation of issues within Antibiotic resistance.
Robert A. Bonomo mainly focuses on Microbiology, Acinetobacter baumannii, Antibiotics, Antibiotic resistance and Multiple drug resistance. His study in Microbiology is interdisciplinary in nature, drawing from both Pseudomonas aeruginosa, Klebsiella pneumoniae, Avibactam, Ceftazidime and Efflux. His studies in Klebsiella pneumoniae integrate themes in fields like Plasmid and Aztreonam.
His Acinetobacter baumannii study combines topics in areas such as Drug development, Drug, Drug resistance and Acinetobacter. His Antibiotics research integrates issues from Pharmacology and Public health. The study incorporates disciplines such as Rescue therapy, Enterobacteriaceae, Function and Enzyme in addition to Antibiotic resistance.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Global Challenge of Multidrug-Resistant Acinetobacter baumannii
Federico Perez;Andrea M. Hujer;Kristine M. Hujer;Brooke K. Decker.
Antimicrobial Agents and Chemotherapy (2007)
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
L Silvia Munoz-Price;L Silvia Munoz-Price;Laurent Poirel;Robert A Bonomo;Robert A Bonomo;Mitchell J Schwaber.
Lancet Infectious Diseases (2013)
Three Decades of β-Lactamase Inhibitors
Sarah M. Drawz;Robert A. Bonomo;Robert A. Bonomo.
Clinical Microbiology Reviews (2010)
International Prospective Study of Klebsiella pneumoniae Bacteremia: Implications of Extended-Spectrum β-Lactamase Production in Nosocomial Infections
David L. Paterson;Wen Chien Ko;Anne Von Gottberg;Sunlta Mohapatra.
Annals of Internal Medicine (2004)
Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum β-Lactamases: Implications for the Clinical Microbiology Laboratory
David L. Paterson;David L. Paterson;Wen-Chien Ko;Anne Von Gottberg;Jose Maria Casellas.
Journal of Clinical Microbiology (2001)
Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa
Robert A. Bonomo;Dora Szabo.
Clinical Infectious Diseases (2006)
Antibiotic Therapy for Klebsiella pneumoniae Bacteremia: Implications of Production of Extended-Spectrum β-Lactamases
David L. Paterson;David L. Paterson;Wen Chien Ko;Anne Von Gottberg;Sunita Mohapatra.
Clinical Infectious Diseases (2004)
10 × '20 Progress—Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America
Helen W. Boucher;George H. Talbot;Daniel K. Benjamin;Daniel K. Benjamin;John Bradley;John Bradley.
Clinical Infectious Diseases (2013)
Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients.
Curtis J. Donskey;Tanvir K. Chowdhry;Michelle T. Hecker;Claudia K. Hoyen.
The New England Journal of Medicine (2000)
Carbapenems: Past, Present, and Future
Krisztina M. Papp-Wallace;Andrea Endimiani;Andrea Endimiani;Andrea Endimiani;Magdalena A. Taracila;Robert A. Bonomo.
Antimicrobial Agents and Chemotherapy (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: